1. Topical to the current climate of the world, lots of co-morbidities are associated with obesity, and many countries spend large sums of money on treating obesity itself and the co-morbidities associated with it. The advantage of non-peptide higher bioavailability. First synthetic GPL-1 type drug.

2. 72 week double blind trial that evaluates the efficacy of the drug. Showing improvements in BP, triglycerides and non-HDL cholesterol with dose-dependent weight loss as well. Safety profile was satisfactory lacking the liver toxicity that other small molecules had

3. Non- peptide agonist, harder for proteases in the stomach to break down and can survive the GI environment and reach systemic circulation without absorption enhancers. Higher bioavailability and absorption intake is not affected by food and water intake. - Binds to the transmembrane GLP-1 receptor rather than the N-terminal.

what is the article about - new pill drug for eliminating skin lesions caused by psoriasis

what is the pharmacology - envudeucitinib TYK2 blocker showing superior efficacy to competitors

what：A 13-year-old with asthma died after repeated hospital visits where her worsening symptoms were allegedly dismissed and care wasn’t well coordinated.

component: t he mechanism of acute asthma

Q2: Large scale phase 3 trial compared with Herceptin plus chemotherapy. Compared to the control (original treatment) the risk of death decreased 28% and extends the overall survival length by 7.2-26.4 months. Although it has an increase in overall survival length, it has still not yet met the OS goal. And, the new treatment has a longer duration of response.

Q3: Old treatment binds with one region of HER2, while the new one binds with two regions. Diarrhoea is one of the adverse effects of the HER2 target therapy.

What is it about? Researchers wanted to understand the mechanisms that underlie the cancer resistance of the bowhead whale - bowhead whale fibroblasts required fewer oncogenic hits to undergo malignant transformation than human fibroblasts. However, bowhead whale cells exhibited enhanced DNA double-strand break repair capacity and fidelity, and lower mutation rates than cells of other mammals.

What is the pharmacology component? Cold-inducible RNA binding protein (CIRBP) - protein that enhances DNA repair. Bowhead whale CIRBP enhanced both non-homologous end joining and homologous recombination repair in human cells, reduced micronuclei formation, promoted DNA end protection, and stimulated end joining in vitro. CIRBP overexpression in Drosophila extended lifespan and improved resistance to irradiation.

https://www.ft.com/content/ea4dfb58-7f5b-49b5-bfc5-ee6f84e5369a

The compound inhibits advillin (AVIL), an actin‑binding protein previously thought to be an undruggable target, and shows particular activity against glioblastoma stem cells, suggesting tumors may find it harder to develop resistance.

Because compound A crosses the blood–brain barrier and hits several key translational benchmarks in preclinical testing, a spinout, Avil Therapeutics, is now optimizing it into a pill formulation with the aim of starting first‑in‑human trials in one to two years, though the researchers stress it is still far from a cure and further work is needed to understand potential resistance.

WVE‑006, the first RNA editing therapy to reach human testing, has shown it can restore production of functional alpha‑1 antitrypsin protein in patients, supporting Wave’s argument that it could potentially offer a “functional cure,” though investors have questioned the strength of the effect and remain cautious, particularly after a rival Korro Bio program in AATD was discontinued for lackluster potency. Wave plans to accelerate regulatory engagement, aiming for discussions with the FDA about a potential accelerated approval pathway by mid‑year and positioning WVE‑006 as a barometer for whether RNA editing can become a viable, safer alternative to DNA editing in genetic medicine.

New approaches are finally moving beyond minoxidil and finasteride: Pelage’s topical PP405 reactivates hair follicle stem cells via lactate‑linked metabolism and showed >20% hair‑density gains in some men in a Phase 2a trial, while Veradermics’ extended‑release oral minoxidil (VDPHL01) aims for consistent exposure with fewer cardiovascular risks and has produced strong hair‑count and patient‑reported improvements so far.

In immune‑mediated alopecia areata, Nektar’s rezpegaldesleukin expands regulatory T cells to reset immune balance, more than doubling hair regrowth versus placebo with a favourable safety profile compared to JAK inhibitors.

Cell‑based regeneration is also advancing: Shiseido’s autologous dermal sheath cup cell therapy is already offered in Japan, and dermal papilla cell–based strategies could ultimately scale to generate new follicles for broader hair restoration.

Overall, the field is shifting from incremental, symptom‑focused drugs toward regenerative, immune‑modulating, and reformulated therapies that could deliver durable regrowth, potentially making hair loss the next breakout “lifestyle” drug category if even one approach proves both effective and safe at scale.